A population‐based study of factors associated with systemic treatment in advanced prostate cancer decedents
Cancer Medicine · 2023-03 · 12 (5) · 5569-5579
DOI: 10.1002/cam4.5401 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 17.11.2022. Verfasst von Jennifer Leigh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada. Hauptthemen laut MEDLINE: Androgen Antagonists, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institute for Clinical Evaluative Sciences, Ministry of Health.
Abstract (Originalsprache)
Introduction
Life‐prolonging therapies (LPTs) are rapidly evolving for the treatment of advanced prostate cancer, although factors associated with real‐world uptake are not well characterized.
Methods
In this cohort of prostate‐cancer decedents, we analyzed factors associated with LPT access. Population‐level databases from Ontario, Canada identified patients 65 years or older with prostate cancer receiving androgen deprivation therapy and who died of prostate cancer between 2013 and 2017. Univariate and multivariable analyses assessed the association between baseline characteristics and receipt of LPT in the 2 years prior to death.
Results
Of 3575 patients who died of prostate cancer, 40.4% ( n = 1443) received LPT, which comprised abiraterone (66.3%), docetaxel (50.3%), enzalutamide (17.2%), radium‐223 (10.0%), and/or cabazitaxel (3.5%). Use of LPT increased by year of death (2013: 22.7%, 2014: 31.8%, 2015: 41.8%, 2016: 49.1%, and 2017: 57.9%, p < 0.0001), driven by uptake of all agents except docetaxel. Adjusted odds of use were higher for patients seen at Regional Cancer Centers (OR: 1.8, 95% CI: 1.5–2.1) and who received prior prostate‐directed therapy (OR: 1.3, 95% CI: 1.0–1.5), but lower with advanced age (≥85: OR: 0.54, 95% CI:0.39–0.75), increased chronic conditions (≥6: OR: 0.62, 95% CI: 0.43–0.92), and long‐term care residency (OR: 0.38, 95% CI: 0.17–0.89). Income, stage at presentation, and distance to the cancer center were not associated with LPT uptake.
Conclusion
In this cohort of prostate cancer‐decedents, real‐world uptake of novel prostate cancer therapies occurred at substantially higher rates for patients receiving care at Regional Cancer Centers, reinforcing the potential benefits for treatment access for patients referred to specialist centers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
- Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
- Nuffield Department of Population Health, University of Oxford, England, UK.
- ICES University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Division of Urology, Department of Surgery, The Ottawa Hospital and University of Ottawa, Ottawa, Ontario, Canada.
ORCID-Profile: Jennifer Leigh
Förderung
- Institute for Clinical Evaluative Sciences
- Ministry of Health
Zitieren
APA
Leigh, J., Qureshi, D., Sucha, E., Mahdavi, R., Kushnir, I., Lavallée, L. T., Bosse, D., Webber, C., Tanuseputro, P., & Ong, M. (2023). A population‐based study of factors associated with systemic treatment in advanced prostate cancer decedents. Cancer Medicine, 12(5), 5569-5579. https://doi.org/10.1002/cam4.5401
Vancouver
Leigh J, Qureshi D, Sucha E, Mahdavi R, Kushnir I, Lavallée LT, et al. A population‐based study of factors associated with systemic treatment in advanced prostate cancer decedents. Cancer Medicine. 2023;12(5):5569-5579. doi:10.1002/cam4.5401
BibTeX
@article{Leigh2023,
author = {Leigh, Jennifer and Qureshi, Danial and Sucha, Ewa and Mahdavi, Roshanak and Kushnir, Igal and Lavallée, Luke T and Bosse, Dominick and Webber, Colleen and Tanuseputro, Peter and Ong, Michael},
title = {A population‐based study of factors associated with systemic treatment in advanced prostate cancer decedents},
journal = {Cancer Medicine},
year = {2023},
volume = {12},
number = {5},
pages = {5569--5579},
doi = {10.1002/cam4.5401}
}
EUVIMED